Loading
Unlearn.AI
Unlearn.AI is a technology company founded in 2017 and based in San Francisco, California, with an additional office in Cambridge, Massachusetts. The company specializes in the intersection of artificial intelligence, biostatistics, and clinical research, focusing on the development of digital twins to enhance clinical trials. Unlearn.AI aims to make clinical trials smarter, faster, and more efficient by eliminating traditional trial and error methods in medicine. The company offers AI-powered digital twins that serve as statistical forecasts for clinical trial participants, replacing traditional placebo groups. Its key products include TwinRCT™, a suite of statistical methods that enables smaller, more efficient trials, and PROCOVA™, a patent-pending method that adjusts for prognostic covariates to optimize sample sizes. Unlearn.AI's technology helps pharmaceutical and biotech companies reduce trial timelines, lower costs, and address ethical concerns related to placebo use, ultimately accelerating the delivery of life-saving treatments.
Funding
Every round, secondary, debt facility or acquisition involving Unlearn.AI that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$5M